Healthcare PE Breaks Record With $191B in 2025 as Venture Funding Recalibrates — Evening Brief – 01.16.26
Global healthcare private equity reached a new peak in 2025, with deal value climbing to a record $191 billion, according to a new annual report from Bain & Company. The surge came even as healthcare venture capital continued to retrench from its post-pandemic highs, underscoring a clear divide between late-stage buyout activity and early-stage risk appetite.
Taken together with Silicon Valley Bank’s 17th annual Healthcare Investments and Exits report, the data point to a maturing investment landscape: buyout firms are leaning into scale and consolidation, while venture investors are becoming more selective.
Bain attributed the record year to a sharp increase in billion-dollar-plus transactions, with 445 healthcare buyouts announced—making 2025 the second-busiest year on record by deal count. Exit activity also rebounded meaningfully, with total exit value jumping to $156 billion from $54 billion in 2024, as sponsor-to-sponsor transactions recovered from a post-pandemic lull.
“Healthcare private equity delivered a record performance last year as large deals spiked and deal count rose across all tiers,” said Kara Murphy, a partner at Bain and co-leader of its healthcare private equity practice.
By sector, biopharma led the market with approximately $80 billion in deal value, up from $55 billion a year earlier. Provider services followed, rising 57% to $62 billion, while healthcare IT emerged as a standout, with deal value in the provider segment doubling to $32 billion.
Venture capital activity moved in the opposite direction. Silicon Valley Bank reported $46.8 billion in healthcare VC investment in 2025, down 12% year over year and well below the $68.3 billion peak reached in 2021. Artificial intelligence dominated what capital was deployed, capturing 46% of all healthcare venture dollars, or more than $18 billion, driven by the funding needs of generative and agentic AI platforms.
“Healthcare venture fundraising has entered a reset,” said Megan Scheffel, noting that investors are increasingly prioritizing clinical validation, revenue visibility, and capital efficiency.
Geographically, private equity strength was broad-based. Europe’s healthcare deal value doubled to $59 billion, North America recorded 26 billion-dollar-plus deals, and Asia Pacific set a new regional record, surpassing its 2021 high by more than 30%.
Looking ahead, Bain partner Nirad Jain cited ample dry powder and aging portfolio assets as tailwinds for 2026—while cautioning that competition will keep pressure on disciplined value creation.